Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection

Antiviral Research

Volumn 96, Issue 3, 2012, Pages 391-404

  Lee, Suki Man Yan ^a   Yen, Hui Ling ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

Author keywords

Antivirals; Cyclooxygenase 2 inhibitors; Immunomodulators; Influenza; Neuraminidase inhibitor resistance

Indexed keywords

2 [3 AZASPIRO(5,5)UNDECANOL] 2 IMIDAZOLINE; AMANTADINE; ANTIVIRUS AGENT; ARBIDOL; BL 1743; CROSS REACTING ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; FAVIPIRAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPENTENYL DIPHOSPHATE; LANINAMIVIR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NSC 109834; NSC 125044; NSC 128164; NSC 95676; OSELTAMIVIR; PERAMIVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN INHIBITOR; RIBAVIRIN; RIMANTADINE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; GENE MUTATION; HUMAN; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ENTRY; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CROSS REACTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOMODULATION; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE INFECTIONS; PYRAZINES; RECEPTORS, CELL SURFACE; VIRAL MATRIX PROTEINS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

EID: 84869139385     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.013     Document Type: Review

References (212)

1. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 2006, 11:971-976.
2. Air G.M. Influenza neuraminidase. Influenza Other Respi. Viruses 2011, 6:245-256.
3. Aldridge J.R., Moseley C.E., Boltz D.A., Negovetich N.J., Reynolds C., Franks J., Brown S.A., Doherty P.C., Webster R.G., Thomas P.G. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl. Acad. Sci. USA 2009, 106:5306-5311.
4. Babu Y.S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliott A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., Montgomery J.A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43:3482-3486.
5. Balannik V., Wang J., Ohigashi Y., Jing X., Magavern E., Lamb R.A., Degrado W.F., Pinto L.H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 2009, 48:11872-11882.
6. Basu D., Walkiewicz M.P., Frieman M., Baric R.S., Auble D.T., Engel D.A. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J. Virol. 2009, 83:1881-1891.
7. Belser J.A., Lu X., Szretter K.J., Jin X., Aschenbrenner L.M., Lee A., Hawley S., Kim do H., Malakhov M.P., Yu M., Fang F., Katz J.M. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 2007, 196:1493-1499.
8. Bloom J.D., Gong L.I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328:1272-1275.
9. Bodian D.L., Yamasaki R.B., Buswell R.L., Stearns J.F., White J.M., Kuntz I.D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993, 32:2967-2978.
10. Boltz D.A., Aldridge J.R., Webster R.G., Govorkova E.A. Drugs in development for influenza. Drugs 2010, 70:1349-1362.
11. Born W.K., Reardon C.L., O'Brien R.L. The function of gammadelta T cells in innate immunity. Curr. Opin. Immunol. 2006, 18:31-38.
12. Bottcher-Friebertshauser E., Freuer C., Sielaff F., Schmidt S., Eickmann M., Uhlendorff J., Steinmetzer T., Klenk H.D., Garten W. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 2010, 84:5605-5614.
13. Bottcher-Friebertshauser E., Stein D.A., Klenk H.D., Garten W. Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J. Virol. 2011, 85:1554-1562.
14. Bottcher E., Freuer C., Steinmetzer T., Klenk H.D., Garten W. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 2009, 27:6324-6329.
15. Bottcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006, 80:9896-9898.
16. Brandes M., Willimann K., Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005, 309:264-268.
17. Brannon T.S., MacRitchie A.N., Jaramillo M.A., Sherman T.S., Yuhanna I.S., Margraf L.R., Shaul P.W. Ontogeny of cyclooxygenase-1 and cyclooxygenase-2 gene expression in ovine lung. Am. J. Physiol. 1998, 274:L66-71.
18. Cady S.D., Schmidt-Rohr K., Wang J., Soto C.S., Degrado W.F., Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463:689-692.
19. Carding S.R., Egan P.J. Gammadelta T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2002, 2:336-345.
20. Carey M.A., Bradbury J.A., Seubert J.M., Langenbach R., Zeldin D.C., Germolec D.R. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol. 2005, 175:6878-6884.
21. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 1994, 84:2068-2101.
22. Chaipan C., Kobasa D., Bertram S., Glowacka I., Steffen I., Tsegaye T.S., Takeda M., Bugge T.H., Kim S., Park Y., Marzi A., Pohlmann S. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83:3200-3211.
23. Chan-Tack K.M., Murray J.S., Birnkrant D.B. Use of ribavirin to treat influenza. N. Engl. J. Med. 2009, 361:1713-1714.
24. Chan M.M., Moore A.R. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 2010, 184:6418-6426.
25. Chan R.W., Chan M.C., Wong A.C., Karamanska R., Dell A., Haslam S.M., Sihoe A.D., Chui W.H., Triana-Baltzer G., Li Q., Peiris J.S., Fang F., Nicholls J.M. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob. Agents Chemother. 2009, 53:3935-3941.
26. Chen W., Calvo P.A., Malide D., Gibbs J., Schubert U., Bacik I., Basta S., O'Neill R., Schickli J., Palese P., Henklein P., Bennink J.R., Yewdell J.W. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 2001, 7:1306-1312.
27. Cheng P.K., To A.P., Leung T.W., Leung P.C., Lee C.W., Lim W.W. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg. Infect. Dis. 2010, 16:155-156.
28. Chong P.H., Seeger J.D., Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med. 2001, 111:390-400.
29. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 2000, 164:1364-1371.
30. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., Silacci C., Fernandez-Rodriguez B.M., Agatic G., Bianchi S., Giacchetto-Sasselli I., Calder L., Sallusto F., Collins P., Haire L.F., Temperton N., Langedijk J.P., Skehel J.J., Lanzavecchia A. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
31. Das K., Aramini J.M., Ma L.C., Krug R.M., Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 2010, 17:530-538.
32. De Clercq E. Another ten stories in antiviral drug discovery (part C): " Old" and " new" antivirals, strategies, and perspectives. Med. Res. Rev. 2009, 29:611-645.
33. de Vries E., Tscherne D.M., Wienholts M.J., Cobos-Jimenez V., Scholte F., Garcia-Sastre A., Rottier P.J., de Haan C.A. Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog. 2011, 7:e1001329.
34. Delogu I., Pastorino B., Baronti C., Nougairede A., Bonnet E., de Lamballerie X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011, 90:99-107.
35. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
36. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St.George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
37. Dias A., Bouvier D., Crepin T., McCarthy A.A., Hart D.J., Baudin F., Cusack S., Ruigrok R.W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009, 458:914-918.
38. Droebner K., Pleschka S., Ludwig S., Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 2011, 92:195-203.
39. Duan S., Boltz D.A., Seiler P., Li J., Bragstad K., Nielsen L.P., Webby R.J., Webster R.G., Govorkova E.A. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 2010, 6:e1001022.
40. Dubois R.M., Slavish P.J., Baughman B.M., Yun M.K., Bao J., Webby R.J., Webb T.R., White S.W. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog. 2012, 8:e1002830.
41. Duval X., van der Werf S., Blanchon T., Mosnier A., Bouscambert-Duchamp M., Tibi A., Enouf V., Charlois-Ou C., Vincent C., Andreoletti L., Tubach F., Lina B., Mentre F., Leport C. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010, 7:e1000362.
42. Ehrhardt C., Marjuki H., Wolff T., Nurnberg B., Planz O., Pleschka S., Ludwig S. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell. Microbiol. 2006, 8:1336-1348.
43. Eichelberger M.C., Hassantoufighi A., Wu M., Li M. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol. J. 2008, 5:109.
44. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H.J., Brandenburg B., Vogels R., Brakenhoff J.P., Kompier R., Koldijk M.H., Cornelissen L.A., Poon L.L., Peiris M., Koudstaal W., Wilson I.A., Goudsmit J. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850.
45. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 1977, 11:946-951.
46. Ermert L., Ermert M., Goppelt-Struebe M., Walmrath D., Grimminger F., Steudel W., Ghofrani H.A., Homberger C., Duncker H., Seeger W. Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am. J. Respir. Cell Mol. Biol. 1998, 18:479-488.
47. Eyers S., Weatherall M., Shirtcliffe P., Perrin K., Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J. R. Soc. Med. 2010, 103:403-411.
48. Faleiro L., Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J. Cell Biol. 2000, 151:951-959.
49. Fiore A.E., Bridges C.B., Cox N.J. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:43-82.
50. Fleming D.M., Verlander N.Q., Elliot A.J., Zhao H., Gelb D., Jehring D., Nguyen-Van-Tam J.S. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol. Infect. 2010, 138:1281-1288.
51. Friesen R.H., Koudstaal W., Koldijk M.H., Weverling G.J., Brakenhoff J.P., Lenting P.J., Stittelaar K.J., Osterhaus A.D., Kompier R., Goudsmit J. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE 2010, 5:e9106.
52. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012.
53. Fukunaga K., Kohli P., Bonnans C., Fredenburgh L.E., Levy B.D. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 2005, 174:5033-5039.
54. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002, 46:977-981.
55. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49:981-986.
56. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82:95-102.
57. Gack M.U., Albrecht R.A., Urano T., Inn K.S., Huang I.C., Carnero E., Farzan M., Inoue S., Jung J.U., Garcia-Sastre A. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
58. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 2010, 285:28403-28409.
59. Gerritz S.W., Cianci C., Kim S., Pearce B.C., Deminie C., Discotto L., McAuliffe B., Minassian B.F., Shi S., Zhu S., Zhai W., Pendri A., Li G., Poss M.A., Edavettal S., McDonnell P.A., Lewis H.A., Maskos K., Mortl M., Kiefersauer R., Steinbacher S., Baldwin E.T., Metzler W., Bryson J., Healy M.D., Philip T., Zoeckler M., Schartman R., Sinz M., Leyva-Grado V.H., Hoffmann H.H., Langley D.R., Meanwell N.A., Krystal M. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc. Natl. Acad. Sci. USA 2011, 108:15366-15371.
60. Ghanem A., Mayer D., Chase G., Tegge W., Frank R., Kochs G., Garcia-Sastre A., Schwemmle M. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 2007, 81:7801-7804.
61. Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006, 16:37-48.
62. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004, 103:199-203.
63. Gubareva L.V., Hayden F.G. The anti-influenza activity of M2 and neuraminidase inhibotors. Influenza Virology: Current Topics 2006, 169-202. Caister Academic Press, England. Y. Kawaoka (Ed.).
64. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183:523-531.
65. Gubareva L.V., Trujillo A.A., Okomo-Adhiambo M., Mishin V.P., Deyde V.M., Sleeman K., Nguyen H.T., Sheu T.G., Garten R.J., Shaw M.W., Fry A.M., Klimov A.I. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir. Ther. 2010, 15:1151-1159.
66. Guilligay D., Tarendeau F., Resa-Infante P., Coloma R., Crepin T., Sehr P., Lewis J., Ruigrok R.W., Ortin J., Hart D.J., Cusack S. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 2008, 15:500-506.
67. Gutierrez R.A., Naughtin M.J., Horm S.V., San S., Buchy P. A(H5N1) virus evolution in South East Asia. Viruses 2009, 1:335-361.
68. Haasbach E., Pauli E.K., Spranger R., Mitzner D., Schubert U., Kircheis R., Planz O. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Res. 2011, 91:304-313.
69. Hale B.G., Randall R.E., Ortin J., Jackson D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89:2359-2376.
70. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 2009, 48(Suppl 1):S3-13.
71. He X., Zhou J., Bartlam M., Zhang R., Ma J., Lou Z., Li X., Li J., Joachimiak A., Zeng Z., Ge R., Rao Z., Liu Y. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 2008, 454:1123-1126.
72. Hedlund M., Aschenbrenner L.M., Jensen K., Larson J.L., Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J. Infect. Dis. 2010, 201:1007-1015.
73. Hernandez J.E., Adiga R., Armstrong R., Bazan J., Bonilla H., Bradley J., Dretler R., Ison M.G., Mangino J.E., Maroushek S., Shetty A.K., Wald A., Ziebold C., Elder J., Hollister A.S., Sheridan W. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin. Infect. Dis. 2011, 52:695-706.
74. Herold S., Steinmueller M., von Wulffen W., Cakarova L., Pinto R., Pleschka S., Mack M., Kuziel W.A., Corazza N., Brunner T., Seeger W., Lohmeyer J. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J. Exp. Med. 2008, 205:3065-3077.
75. Hoopes J.D., Driebe E.M., Kelley E., Engelthaler D.M., Keim P.S., Perelson A.S., Rong L., Went G.T., Nguyen J.T. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS ONE 2011, 6:e29778.
76. Hurt A.C., Chotpitayasunondh T., Cox N.J., Daniels R., Fry A.M., Gubareva L.V., Hayden F.G., Hui D.S., Hungnes O., Lackenby A., Lim W., Meijer A., Penn C., Tashiro M., Uyeki T.M., Zambon M. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 2012, 12:240-248.
77. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
78. Ikematsu H., Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev. Anti Infect. Ther. 2011, 9:851-857.
79. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
80. Ilyushina N.A., Hoffmann E., Salomon R., Webster R.G., Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 2007, 12:363-370.
81. Iversen M.B., Paludan S.R. Mechanisms of type III interferon expression. J. Interferon Cytokine Res. 2010, 30:573-578.
82. Jablonski J.J., Basu D., Engel D.A., Geysen H.M. Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1. Bioorg. Med. Chem. 2012, 20:487-497.
83. Jagger B.W., Wise H.M., Kash J.C., Walters K.A., Wills N.M., Xiao Y.L., Dunfee R.L., Schwartzman L.M., Ozinsky A., Bell G.L., Dalton R.M., Lo A., Efstathiou S., Atkins J.F., Firth A.E., Taubenberger J.K., Digard P. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 2012, 337:199-204.
84. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
85. Jones J.C., Turpin E.A., Bultmann H., Brandt C.R., Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 2006, 80:11960-11967.
86. Julkunen I., Sareneva T., Pirhonen J., Ronni T., Melen K., Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 2001, 12:171-180.
87. Kao R.Y., Yang D., Lau L.S., Tsui W.H., Hu L., Dai J., Chan M.P., Chan C.M., Wang P., Zheng B.J., Sun J., Huang J.D., Madar J., Chen G., Chen H., Guan Y., Yuen K.Y. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol. 2010, 28:600-605.
88. Kawaoka Y., Krauss S., Webster R.G. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J. Virol. 1989, 63:4603-4608.
89. Khan K.N., Stanfield K., Trajkovic D., Harris R.K. Cyclooxygenase-2 expression in inflammatory lung lesions of nonhuman primates. Vet. Pathol. 2000, 37:512-516.
90. Kim, C.U., Lew, W., Williams, M., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M.S., Mendel, D., Li, W., Tai, L., Escarpe, P., Cundy, K.C., Eisenberg, E.J., Lacy, S., Sidwell, R.W., Stevens, R.C., Laver, G.W., 1996. New potent, orally active neuraminidase inhibitors as anti-influenza agents: in vitro and in vivo activity of GS4071 and analogs. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
91. Kim W.Y., Young Suh G., Huh J.W., Kim S.H., Kim M.J., Kim Y.S., Kim H.R., Ryu Y.J., Han M.S., Ko Y.G., Chon G.R., Lee K.H., Choi S.H., Hong S.B. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob. Agents Chemother. 2011, 55:5703-5709.
92. Kiso M., Ozawa M., Le M.T., Imai H., Takahashi K., Kakugawa S., Noda T., Horimoto T., Kawaoka Y. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J. Virol. 2011, 85:4667-4672.
93. Kiso M., Shinya K., Shimojima M., Takano R., Takahashi K., Katsura H., Kakugawa S., Le M.T., Yamashita M., Furuta Y., Ozawa M., Kawaoka Y. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 2010, 6:e1001079.
94. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 1994, 91:7355-7359.
95. Koudstaal W., Koldijk M.H., Brakenhoff J.P., Cornelissen L.A., Weverling G.J., Friesen R.H., Goudsmit J. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice. Viable alternative to oseltamivir. J. Infect. Dis. 2009, 200:1870-1873.
96. Kowalinski E., Zubieta C., Wolkerstorfer A., Szolar O.H., Ruigrok R.W., Cusack S. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of Influenza pH1N1 (2009) polymerase. PLoS Pathog. 2012, 8:e1002831.
97. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003, 4:1169-1176.
98. Kubo S., Tomozawa T., Kakuta M., Tokumitsu A., Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 2010, 54:1256-1264.
99. Kurokawa M., Tsurita M., Brown J., Fukuda Y., Shiraki K. Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice. Antiviral Res. 2002, 56:183-188.
100. Kurtz S., Luo G., Hahnenberger K.M., Brooks C., Gecha O., Ingalls K., Numata K., Krystal M. Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob. Agents Chemother. 1995, 39:2204-2209.
101. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
102. Kwong J.C., Li P., Redelmeier D.A. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS ONE 2009, 4:e8087.
103. Lackenby, A., Hungnes, O., Dudman, S.G., Meijer, A., Paget, W.J., Hay, A.J., Zambon, M.C., 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13, pii: 8026.
104. Lamb R.A., Pinto L.H. The proton selective ion channels of influenza A and B viruses. Influenza Virology: Current Topics 2006, 65-93. Caister Academic Press, England. Y. Kawaoka (Ed.).
105. Larson J.L., Kang S.K., Choi B.I., Hedlund M., Aschenbrenner L.M., Cecil B., Machado G., Nieder M., Fang F. A safety evaluation of DAS181, a sialidase fusion protein, in rodents. Toxicol. Sci. 2011, 122:567-578.
106. Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010, 6:e1001005.
107. Lee S.M., Cheung C.Y., Nicholls J.M., Hui K.P., Leung C.Y., Uiprasertkul M., Tipoe G.L., Lau Y.L., Poon L.L., Ip N.Y., Guan Y., Peiris J.S. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J. Infect. Dis. 2008, 198:525-535.
108. Lee S.M., Gai W.W., Cheung T.K., Peiris J.S. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res. 2011, 91:330-334.
109. Leibbrandt A., Meier C., Konig-Schuster M., Weinmullner R., Kalthoff D., Pflugfelder B., Graf P., Frank-Gehrke B., Beer M., Fazekas T., Unger H., Prieschl-Grassauer E., Grassauer A. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS ONE 2010, 5:e14320.
110. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009, 81:132-140.
111. Li Q., Qi J., Zhang W., Vavricka C.J., Shi Y., Wei J., Feng E., Shen J., Chen J., Liu D., He J., Yan J., Liu H., Jiang H., Teng M., Li X., Gao G.F. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 2010, 17:1266-1268.
112. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol. Chem. 2011, 392:837-847.
113. Lukkarinen H., Laine J., Aho H., Asikainen E., Penttinen P., Kaapa P. Inhibition of COX-2 aggravates neutrophil migration and pneumocyte apoptosis in surfactant-depleted rat lungs. Pediatr. Res. 2006, 59:412-417.
114. Malakhov M.P., Aschenbrenner L.M., Smee D.F., Wandersee M.K., Sidwell R.W., Gubareva L.V., Mishin V.P., Hayden F.G., Kim D.H., Ing A., Campbell E.R., Yu M., Fang F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 2006, 50:1470-1479.
115. Mao H., Tu W., Liu Y., Qin G., Zheng J., Chan P.L., Lam K.T., Peiris J.S., Lau Y.L. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J. Virol. 2010, 84:4148-4157.
116. Mao H., Tu W., Qin G., Law H.K., Sia S.F., Chan P.L., Liu Y., Lam K.T., Zheng J., Peiris M., Lau Y.L. Influenza virus directly infects human natural killer cells and induces cell apoptosis. J. Virol. 2009, 83:9215-9222.
117. Marjuki H., Yen H.L., Franks J., Webster R.G., Pleschka S., Hoffmann E. Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf/MEK/ERK signal cascade. Virol. J. 2007, 4:134.
118. Marsolais D., Hahm B., Edelmann K.H., Walsh K.B., Guerrero M., Hatta Y., Kawaoka Y., Roberts E., Oldstone M.B., Rosen H. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol. Pharmacol. 2008, 74:896-903.
119. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78:12665-12667.
120. Matsuyama S., Nagata N., Shirato K., Kawase M., Takeda M., Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010, 84:12658-12664.
121. Mazur I., Wurzer W.J., Ehrhardt C., Pleschka S., Puthavathana P., Silberzahn T., Wolff T., Planz O., Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell. Microbiol. 2007, 9:1683-1694.
122. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 2000, 47:1-17.
123. Memoli M.J., Davis A.S., Proudfoot K., Chertow D.S., Hrabal R.J., Bristol T., Taubenberger J.K. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 2011, 203:348-357.
124. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 2006, 50:2395-2402.
125. Moscona A., Porotto M., Palmer S., Tai C., Aschenbrenner L., Triana-Baltzer G., Li Q.X., Wurtman D., Niewiesk S., Fang F. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J. Infect. Dis. 2010, 202:234-241.
126. Moss, R., Steigbigel, R., Wurtman, D., Hansen, C., Tranel, K.C., M., Larson, J., Sanders, R., Hawley, S., Li, T., Fang, F., 2011. A phase 2A dose-ranging clinical trial of DAS181 for treatment of influenza in health dults. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
127. Mould J.A., Paterson R.G., Takeda M., Ohigashi Y., Venkataraman P., Lamb R.A., Pinto L.H. Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. Dev. Cell 2003, 5:175-184.
128. Nagata K., Kawaguchi A., Naito T. Host factors for replication and transcription of the influenza virus genome. Rev. Med. Virol. 2008, 18:247-260.
129. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., Blair P.J., de Jong M.D., Prichard M.N., Went G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010, 5:e9332.
130. Obayashi E., Yoshida H., Kawai F., Shibayama N., Kawaguchi A., Nagata K., Tame J.R., Park S.Y. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 2008, 454:1127-1131.
131. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
132. Palese P., Shaw M. Orthomyxoviridae: the viruses and their replication. Fields Virology 2007, 1647-1690. Lippincott Williams & Wilkins, Philadelphia, PA. D.M. Knipe, P.M. Howley (Eds.).
133. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 2005, 107:165-171.
134. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
135. Pinto R., Herold S., Cakarova L., Hoegner K., Lohmeyer J., Planz O., Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011, 92:45-56.
136. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
137. Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 2001, 3:301-305.
138. Qin G., Mao H., Zheng J., Sia S.F., Liu Y., Chan P.L., Lam K.T., Peiris J.S., Lau Y.L., Tu W. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J. Infect. Dis. 2009, 200:858-865.
139. Rameix-Welti M.A., Munier S., Le Gal S., Cuvelier F., Agou F., Enouf V., Naffakh N., van der Werf S. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir. Ther. 2011, 16:597-603.
140. Resa-Infante P., Jorba N., Coloma R., Ortin J. The influenza virus RNA synthesis machine: advances in its structure and function. RNA Biol. 2011, 8:207-215.
141. Riner A., Chan-Tack K.M., Murray J.S. Original research: intravenous ribavirin - review of the FDA's emergency investigational new drug database (1997-2008) and literature review. Postgrad. Med. 2009, 121:139-146.
142. Rivera J., Proia R.L., Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 2008, 8:753-763.
143. Rogers G.N., Paulson J.C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 1983, 127:361-373.
144. Rossignol J.F., La Frazia S., Chiappa L., Ciucci A., Santoro M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 2009, 284:29798-29808.
145. Rudrawar S., Dyason J.C., Rameix-Welti M.A., Rose F.J., Kerry P.S., Russell R.J., van der Werf S., Thomson R.J., Naffakh N., von Itzstein M. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 2010, 1:113.
146. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
147. Seibert C.W., Kaminski M., Philipp J., Rubbenstroth D., Albrecht R.A., Schwalm F., Stertz S., Medina R.A., Kochs G., Garcia-Sastre A., Staeheli P., Palese P. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 2010, 84:11219-11226.
148. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
149. Sheu T.G., Fry A.M., Garten R.J., Deyde V.M., Shwe T., Bullion L., Peebles P.J., Li Y., Klimov A.I., Gubareva L.V. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J. Infect. Dis. 2011, 203:13-17.
150. Shi L., Xiong H., He J., Deng H., Li Q., Zhong Q., Hou W., Cheng L., Xiao H., Yang Z. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch. Virol. 2007, 152:1447-1455.
151. Shobugawa, Y., Saito, R., Sato, I., Kawashima, T., Dapat, C., Dapat, I.C., Kondo, H., Suzuki, Y., Saito, K., Suzuki, H., in press. Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J. Infect. Chemother.
152. Shortridge K.F., Stuart-Harris C.H. An influenza epicentre?. Lancet 1982, 2:812-813.
153. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., Robins R.K. Broad-spectrum antiviral activity of virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972, 177:705-706.
154. Sielaff F., Bottcher-Friebertshauser E., Meyer D., Saupe S.M., Volk I.M., Garten W., Steinmetzer T. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg. Med. Chem. Lett. 2011, 21:4860-4864.
155. Skehel J.J., Waterfield M.D. Studies on the primary structure of the influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 1975, 72:93-97.
156. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
157. Smee D.F., Bailey K.W., Wong M.H., O'Keefe B.R., Gustafson K.R., Mishin V.P., Gubareva L.V. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res. 2008, 80:266-271.
158. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Morrey J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53:2120-2128.
159. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Tarbet E.B., Morrey J.D., Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 2010, 54:126-133.
160. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., Ma S.K., Cheung C.L., Raghwani J., Bhatt S., Peiris J.S., Guan Y., Rambaut A. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
161. Sorbello A., Jones S.C., Carter W., Struble K., Boucher R., Truffa M., Birnkrant D., Gada N., Camilli S., Chan I., Dallas S., Scales T., Kosko R., Thompson E., Goodman J., Francis H., Dal Pan G. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin. Infect. Dis. 2012, 55:1-7.
162. Starko K.M. Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence. Clin. Infect. Dis. 2009, 49:1405-1410.
163. Stech O., Veits J., Weber S., Deckers D., Schroer D., Vahlenkamp T.W., Breithaupt A., Teifke J., Mettenleiter T.C., Stech J. Acquisition of a polybasic hemagglutinin cleavage site by a low-pathogenic avian influenza virus is not sufficient for immediate transformation into a highly pathogenic strain. J. Virol. 2009, 83:5864-5868.
164. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258:1-20.
165. Stieneke-Grober A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., Klenk H.D., Garten W. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 1992, 11:2407-2414.
166. Su B., Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr. Opin. Immunol. 1996, 8:402-411.
167. Su C.Y., Cheng T.J., Lin M.I., Wang S.Y., Huang W.I., Lin-Chu S.Y., Chen Y.H., Wu C.Y., Lai M.M., Cheng W.C., Wu Y.T., Tsai M.D., Cheng Y.S., Wong C.H. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc. Natl. Acad. Sci. USA 2010, 107:19151-19156.
168. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
169. Teijaro J.R., Turner D., Pham Q., Wherry E.J., Lefrancois L., Farber D.L. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 2011, 187:5510-5514.
170. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., ter Meulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS ONE 2008, 3:e3942.
171. Tomassini J., Selnick H., Davies M.E., Armstrong M.E., Baldwin J., Bourgeois M., Hastings J., Hazuda D., Lewis J., McClements W., et al. Inhibition of cap (m7G pppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob. Agents Chemother. 1994, 38:2827-2837.
172. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
173. Triana-Baltzer G.B., Gubareva L.V., Klimov A.I., Wurtman D.F., Moss R.B., Hedlund M., Larson J.L., Belshe R.B., Fang F. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 2009, 4:e7838.
174. Triana-Baltzer G.B., Gubareva L.V., Nicholls J.M., Pearce M.B., Mishin V.P., Belser J.A., Chen L.M., Chan R.W., Chan M.C., Hedlund M., Larson J.L., Moss R.B., Katz J.M., Tumpey T.M., Fang F. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009, 4:e7788.
175. Triana-Baltzer G.B., Sanders R.L., Hedlund M., Jensen K.A., Aschenbrenner L.M., Larson J.L., Fang F. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J. Antimicrob. Chemother. 2011, 66:15-28.
176. Tu W., Zheng J., Liu Y., Sia S.F., Liu M., Qin G., Ng I.H., Xiang Z., Lam K.T., Peiris J.S., Lau Y.L. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J. Exp. Med. 2011, 208:1511-1522.
177. Vanderlinden E., Goktas F., Cesur Z., Froeyen M., Reed M.L., Russell C.J., Cesur N., Naesens L. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 2010, 84:4277-4288.
178. Vavricka C.J., Li Q., Wu Y., Qi J., Wang M., Liu Y., Gao F., Liu J., Feng E., He J., Wang J., Liu H., Jiang H., Gao G.F. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011, 7:e1002249.
179. Viasus D., Pano-Pardo J.R., Cordero E., Campins A., Lopez-Medrano F., Villoslada A., Farinas M.C., Moreno A., Rodriguez-Bano J., Oteo J.A., Martinez-Montauti J., Torre-Cisneros J., Segura F., Carratala J. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J. Infect. 2011, 62:193-199.
180. Vignuzzi M., Stone J.K., Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005, 107:173-181.
181. Vijaykrishna D., Smith G.J., Pybus O.G., Zhu H., Bhatt S., Poon L.L., Riley S., Bahl J., Ma S.K., Cheung C.L., Perera R.A., Chen H., Shortridge K.F., Webby R.J., Webster R.G., Guan Y., Peiris J.S. Long-term evolution and transmission dynamics of swine influenza A virus. Nature 2011, 473:519-522.
182. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
183. Walkiewicz M.P., Basu D., Jablonski J.J., Geysen H.M., Engel D.A. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J. Gen. Virol. 2011, 92:60-70.
184. Walsh K.B., Teijaro J.R., Wilker P.R., Jatzek A., Fremgen D.M., Das S.C., Watanabe T., Hatta M., Shinya K., Suresh M., Kawaoka Y., Rosen H., Oldstone M.B. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. USA 2011, 108:12018-12023.
185. Wang J., Cady S.D., Balannik V., Pinto L.H., DeGrado W.F., Hong M. Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J. Am. Chem. Soc. 2009, 131:8066-8076.
186. Wang J., Qiu J.X., Soto C., DeGrado W.F. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr. Opin. Struct. Biol. 2011, 21:68-80.
187. Wang T.T., Palese P. Biochemistry. Catching a moving target. Science 2011, 333:834-835.
188. Wang X., Li M., Zheng H., Muster T., Palese P., Beg A.A., Garcia-Sastre A. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J. Virol. 2000, 74:11566-11573.
189. Ward P., Small I., Smith J., Suter P., Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. The Journal of antimicrobial chemotherapy 2005, 55(Suppl 1):i5-i21.
190. Watanabe T., Watanabe S., Kawaoka Y. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe 2010, 7:427-439.
191. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992, 56:152-179.
192. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 2001, 7:687-692.
193. Whitehead T.A., Chevalier A., Song Y., Dreyfus C., Fleishman S.J., De Mattos C., Myers C.A., Kamisetty H., Blair P., Wilson I.A., Baker D. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat. Biotechnol. 2012, 30:543-548.
194. Wiesener N., Zimmer C., Jarasch-Althof N., Wutzler P., Henke A. Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate. Med. Microbiol. Immunol. 2011, 200:115-126.
195. Wilborn J., DeWitt D.L., Peters-Golden M. Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages. Am. J. Physiol. 1995, 268:L294-301.
196. Wise H.M., Foeglein A., Sun J., Dalton R.M., Patel S., Howard W., Anderson E.C., Barclay W.S., Digard P. A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J. Virol. 2009, 83:8021-8031.
197. Wolff T., Ludwig S. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. J. Interferon Cytokine Res. 2009, 29:549-557.
198. Wong D.D., Choy K.T., Chan R.W., Sia S.F., Chiu H.P., Cheung P.P., Chan M.C., Peiris J.S., Yen H.L. Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. J. Virol. 2012, 86:10558-10570.
199. Wunderlich K., Mayer D., Ranadheera C., Holler A.S., Manz B., Martin A., Chase G., Tegge W., Frank R., Kessler U., Schwemmle M. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS ONE 2009, 4:e7517.
200. Wurzer W.J., Ehrhardt C., Pleschka S., Berberich-Siebelt F., Wolff T., Walczak H., Planz O., Ludwig S. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J. Biol. Chem. 2004, 279:30931-30937.
201. Wurzer W.J., Planz O., Ehrhardt C., Giner M., Silberzahn T., Pleschka S., Ludwig S. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J. 2003, 22:2717-2728.
202. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
203. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 2005, 49:4075-4084.
204. Yen H.L., Ilyushina N.A., Salomon R., Hoffmann E., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 2007, 81:12418-12426.
205. Yoshida R., Igarashi M., Ozaki H., Kishida N., Tomabechi D., Kida H., Ito K., Takada A. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 2009, 5:e1000350.
206. Younkin S.W., Betts R.F., Roth F.K., Douglas R.G. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob. Agents Chemother. 1983, 23:577-582.
207. Yu Y., Garg S., Yu P.A., Kim H.J., Patel A., Merlin T., Redd S., Uyeki T.M. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin. Infect. Dis. 2012, 55:8-15.
208. Yuan P., Bartlam M., Lou Z., Chen S., Zhou J., He X., Lv Z., Ge R., Li X., Deng T., Fodor E., Rao Z., Liu Y. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009, 458:909-913.
209. Zhang H. Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J. Antimicrob. Chemother. 2008, 62:219-223.
210. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., Chen H.L., Wong S.S., Lau S.K., Woo P.C., Chan K.H., Jin D.Y., Yuen K.Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA 2008, 105:8091-8096.
211. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Suppression of influenza virus replication in infected mice by protease inhibitors. J. Gen. Virol. 1984, 65(Pt 1):191-196.
212. Zoidis G., Kolocouris N., Kelly J.M., Prathalingam S.R., Naesens L., De Clercq E. Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines. Eur. J. Med. Chem. 2010, 45:5022-5030.